Optison (Perflutren)

Perflutren, the active ingredient in Optison, is an ultrasound contrast agent presented as a sterile suspension for injection for intravenous use. It enhances visualization of cardiac structures during echocardiography, aiding diagnostic imaging of the heart and supporting accurate assessment of cardiac function.

GNH USA supplies Optison as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and imaging centres worldwide, ensuring quality assurance, regulatory compliance and reliable cold‑chain logistics for this injectable contrast agent.

Optison (perflutren) is employed in cardiac imaging to improve ultrasound contrast during echocardiographic procedures.

- Echocardiography: enhances endocardial border definition and improves assessment of ventricular function. - Stress echocardiography: provides clearer contrast during pharmacologic or exercise stress testing for myocardial perfusion evaluation. - Cardiac ultrasound imaging: facilitates detailed visualization of cardiac chambers, valves, and intracardiac masses.

Optison may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Mild headache: transient discomfort occurring shortly after injection. - Nausea or vomiting: gastrointestinal upset that resolves spontaneously. - Flushing or warmth: brief sensation of heat on the face or neck. - Transient hypotension: temporary drop in blood pressure without lasting effects. - Mild dyspnea: short‑lasting shortness of breath during administration.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical intervention. - Severe hypotension: marked blood pressure fall that may need vasopressor support. - Cardiac arrhythmia: abnormal heart rhythm potentially necessitating monitoring or treatment.

Prior to administration, clinicians should observe several precautions to minimize risk.

- Hypersensitivity screening: avoid use in patients with known allergy to perflutren or its excipients. - Pulmonary hypertension: use with caution; monitor for worsening respiratory status. - Unstable cardiac conditions: defer administration in patients with acute myocardial infarction or severe heart failure. - Vital sign monitoring: observe blood pressure, heart rate and oxygen saturation during and after injection. - Reconstitution integrity: ensure suspension is gently mixed, do not shake vigorously. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Optison can interact with certain medications; awareness of major and moderate interactions helps ensure safe use.

Major Interactions (Avoid): - Concurrent use of other ultrasound contrast agents: increases risk of additive adverse reactions. - Known severe allergic reaction to albumin-containing products: may precipitate hypersensitivity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask heart‑rate changes during stress testing. - ACE inhibitors or ARBs: potential for additive hypotensive effect. - Nitrates: may enhance vasodilatory response leading to low blood pressure. - Diuretics: altered intravascular volume may affect contrast distribution.